Tracking tumor-specific CD8 T cell responses
Publication information:
Burke K, Markson S, Sharpe A. Tracking tumor-specific CD8 T cell responses. Trends Immunol. 2023;44(5):326–328. doi:10.1016/j.it.2023.03.012
Abstract
In a recent article, Puig-Saus et al. computationally predict and experimentally validate neoantigen-specific T cell responses in patients with melanoma. They identify a restricted set of neoantigens recognized by polyclonal CD8+ T cells as a unique feature of anti-PD-1 responders and engineer autologous tumor-responsive T cells expressing neoantigen-specific TCRs, providing proof-of-concept for future cellular therapies.